Chemical Structure (A00604ff 041d 4ad4 A3bb D0911bf0727e 01)
Terazosin Hydrochloride
Product Images NDC 21695-812
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 21695-812). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (A00604ff 041d 4ad4 A3bb D0911bf0727e 02)
This is a summary of the results of Study 1, with Figure 1 showing the mean change in Total Symptom Score from baseline and mean increase in Peak Flow Rate (mLsec) from baseline. The study evaluated the effectiveness of Terazosin and included a month-long treatment phase. The baseline values can be found in the table above. The asterisk indicates a statistically significant difference with a p-value less than 0.05 when compared to the placebo group.*
Figure 2 (A00604ff 041d 4ad4 A3bb D0911bf0727e 03)
This is a figure of a long-term, open-label, non-placebo controlled study that shows the mean change in total symptom score from baseline over a period of 30 months. The study involved 494 participants and the graph shows a decrease in symptom score over time, with a statistically significant improvement from baseline after 7 months. The baseline mean symptom score was 10.7.*
Figure 3 (A00604ff 041d 4ad4 A3bb D0911bf0727e 04)
The figure represents the mean change in peak flow rate from baseline in a long-term open-label study. The study was not placebo-controlled and the sample size is not available. The mean change from baseline at different months is shown on the graph with a statistical significance level indicated by +p<005 vs. baseline. The baseline mean was 99.*
Terazosin HCl 2mg (A00604ff 041d 4ad4 A3bb D0911bf0727e 05)
This is a description of a drug called Terazosin HCl Peel. It comes in the form of capsules containing 2mg of Terazosin HCl each. The product is manufactured by Cadista Pharmaceuticals, Inc. and packaged by Physician Partner. The capsules are ivory opaque cap and body printed with "TL 384" in black ink. The product ID is PT081290, and it is available by prescription only. This drug should be stored at controlled room temperature. There is a cautionary instruction to keep the medication out of reach of children.*
Terazosin HCl 5mg (A00604ff 041d 4ad4 A3bb D0911bf0727e 06)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
